EGFR and adenocarcinoma: Akamatsu et al. investigated the impact of outcomes according to EGFR mutation status in patients with stage III Adenocarcinoma, and found that those with EGFR mutations tended to develop BM as compared to those with wild-type EGFR after concurrent chemoradiotherapy (6/13 versus 4/31, p = 0.04).